<DOC>
	<DOCNO>NCT03106454</DOCNO>
	<brief_summary>Since introduction combine hormonal contraceptive pill , dosages ethinyl estradiol ( EE ) steadily decrease 150mcg 20mcg attempt improve risk profile associate COC . In 2010 , Food Drug Administration approve oral contraceptive pill contain EE 10mcg/NET acetate 1mg ( Tradename Lo loestrin ) . However , study compare formulation pill contain either high dos estrogen progestin alone . It know whether EE 10mcg sufficient prevent follicular development support endometrium well high dos EE . This trial address question whether oral contraceptive pill EE 10mcg/Norethindrone acetate 1mg good suppress ovulation well side effect profile progestin pill nearly equal dose norethindrone .</brief_summary>
	<brief_title>Ovulation Incidence Oral Contraceptive Users</brief_title>
	<detailed_description>Use combine hormonal contraceptive ( CHC ) contain estrogen associate venous thromboembolic event . In effort decrease risk estrogen , dose ethinyl estradiol ( EE ) contain combined oral contraceptive ( COC ) pills decrease substantially &gt; 100mcg 20mcg . In 2012 , COC 10mcg EE ( Tradename LoLoestrin ) approve Food Drug Administration . However , study compare formulation pill contain progestin alone determine low dose EE decrease ovulation improves unscheduled uterine bleeding beyond see progestin pill ( POP ) . We aim compare COC EE 10mcg/norethindrone ( NET ) acetate 1mg POP contain nearly equal amount progestin ( norethindrone 1.05mg ) . The objective study compare incidence ovulation among user COC EE10mcg/NET acetate 1mg user POP nearly identical progestin dose NET 1.05mg . We plan recruit 58 woman age 18 45 year old , ovulatory baseline base serum progesterone level . Subjects randomized take either COC contain EE 10mcg/NET acetate 1mg POP contain NET 1.05mg one month . During month study treatment , measure ovulation incidence use single serum progesterone level &gt; =4.0ng/dl , sperm penetration cervical mucus use Eggert Kruse classification system , pill compliance NET serum level , side effect include unscheduled uterine bleeding via subject daily diary . Our primary outcome , ovulation incidence , compare study arm . Secondary outcome compare cervical mucus quality , sperm penetration cervical mucus , side effect ( include uterine bleeding ) , pill compliance user two pill .</detailed_description>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Ferrous fumarate</mesh_term>
	<mesh_term>Contraceptives , Oral , Combined</mesh_term>
	<criteria>Reproductive age woman 1845 year old . Menstrual cycle length 2535days BMI less equal 40 English Spanish speaking Pregnant breastfeed previous 3 month . Use OC , hormonal vaginal ring patch , levonorgestrel contain intrauterine device , etonogestrel implant previous 1 month . No use depot medroxyprogesterone acetate ( DMPA ) injection previous 6 month least one menses since discontinuation . Medical contraindication estrogen progestin use . Specifically : smoking among participant 35 year old , migraine aura , history blood clot , ischemic heart disease , stroke , breast cancer , cervical cancer , liver disease , symptomatic gallbladder disease , uncontrolled hypertension , antiphospholipid antibody syndrome , hyperlipidemia , diabetes end organ damage ( retinopathy , nephropathy , neuropathy ) diagnosis &gt; 20 year ago , organ transplant Desire become pregnant next 4 month</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>